Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Understand Novel Biomarkers in Researching Dementia
Sponsor: Washington University School of Medicine
Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Official title: Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1800
Start Date
2024-08-14
Completion Date
2028-12
Last Updated
2026-01-16
Healthy Volunteers
Yes
Interventions
Clinical tau PET
Tau PET (flortaucipir)
Clinical amyloid test
Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
Research blood collection
Research blood assays for amyloid, tau, and neurodegeneration
Cognitive assessments
Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States